J&J offers $5.5B to settle talc lawsuits. The deal would close a legal fight dating to 2009. A bankruptcy judge must still approve the settlement.
Alpha Score of 62 reflects moderate overall profile with strong momentum, weak value, moderate quality, moderate sentiment.
Johnson & Johnson on Monday offered to pay up to $5.5 billion to resolve tens of thousands of lawsuits claiming its talc-based baby powder and other products caused ovarian cancer. The proposed settlement would close a legal fight that has dogged the healthcare giant for more than a decade.
J&J has denied that its talc products caused cancer and has already switched its baby powder formula to cornstarch. Erik Haas, the company's vice president of litigation, called the allegations "meritless" in a statement. He said J&J was confident it would have "ultimately prevailed with further litigation," given its track record in court, but that the settlement "allows the company to put this matter behind it."
The offer comes after a federal court ruling in July that questioned whether individual plaintiffs could prove talc was the direct cause of their ovarian cancer. That decision handed J&J a legal win, but the company still faced a mountain of claims.
Lawsuits date back to 2009. Plaintiffs and their survivors have argued that J&J's talc products were contaminated with asbestos, a known carcinogen that occurs naturally near talc deposits. The company has repeatedly said its talc is safe and free of asbestos, citing studies.
J&J stopped selling talc-based baby powder in the U.S. in 2020 and globally in 2022, switching to a cornstarch version. The settlement, if approved by a bankruptcy court, would resolve claims through a prepackaged bankruptcy filing by a subsidiary.
The offer is the latest attempt by a major company to use bankruptcy to settle mass tort litigation. A previous $8.9 billion settlement attempt by J&J was rejected by courts in 2023. The new $5.5 billion figure is lower but comes with support from a majority of plaintiffs' lawyers, Haas said.
J&J shares rose 1.2% in early trading on the news. The settlement still requires approval from a bankruptcy judge and a vote by claimants.
J&J's Alpha Score stands at 61 out of 100, a Moderate reading, reflecting the unresolved legal overhang balanced by the company's diversified healthcare business. The stock page is JNJ stock page.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.